Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10–17 years of age: Results from a randomised, controlled, double-blind trial
Author:
- XxxXXXxx
- 1 December 2013
- Vol. 31 (51) , 6136-6143
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline Biologicals SA
This publication has 17 references indexed in Scilit:
- Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 YearsJournal of Adolescent Health, 2012
- Efficacy Results of a Trial of a Herpes Simplex VaccineNew England Journal of Medicine, 2012
- The safety evaluation of adjuvants during vaccine development: The AS04 experienceVaccine, 2011
- Herpes Simplex Virus Type 2 Enhances HIV-1 Susceptibility by Affecting Langerhans Cell FunctionThe Journal of Immunology, 2010
- Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006Sexually Transmitted Infections, 2009
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccinesVaccine, 2008
- Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patientsExpert Opinion on Biological Therapy, 2008
- Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes VaccineClinical Infectious Diseases, 2005
- Glycoprotein-D–Adjuvant Vaccine to Prevent Genital HerpesNew England Journal of Medicine, 2002
- Human Immunodeficiency Virus Infection and Genital Ulcer Disease in South AfricaSexually Transmitted Diseases, 2000